vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and VARONIS SYSTEMS INC (VRNS). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $173.1M, roughly 1.1× VARONIS SYSTEMS INC). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 26.9%). VARONIS SYSTEMS INC produced more free cash flow last quarter ($49.0M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 15.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Varonis Systems, Inc. is a software company based in Miami, Florida with R&D offices in Herzliya, Israel. The company’s Data Security Platform analyzes data and data activity using the insights to identify data exposure risks stemming from access permissions and software-as-a-service (SaaS) app configurations, triggering automated remediation capabilities in response.
AXSM vs VRNS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $173.1M |
| Net Profit | $-28.6M | — |
| Gross Margin | — | 76.0% |
| Operating Margin | -13.8% | -1.7% |
| Net Margin | -14.6% | — |
| Revenue YoY | 65.0% | 26.9% |
| Net Profit YoY | 61.9% | — |
| EPS (diluted) | $-0.55 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $173.1M | ||
| Q4 25 | $196.0M | $173.4M | ||
| Q3 25 | $171.0M | $161.6M | ||
| Q2 25 | $150.0M | $152.2M | ||
| Q1 25 | $121.5M | $136.4M | ||
| Q4 24 | $118.8M | $158.5M | ||
| Q3 24 | $104.8M | $148.1M | ||
| Q2 24 | $87.2M | $130.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $-27.8M | ||
| Q3 25 | $-47.2M | $-29.9M | ||
| Q2 25 | $-48.0M | $-35.8M | ||
| Q1 25 | $-59.4M | $-35.8M | ||
| Q4 24 | $-74.9M | $-13.0M | ||
| Q3 24 | $-64.6M | $-18.3M | ||
| Q2 24 | $-79.3M | $-23.9M |
| Q1 26 | — | 76.0% | ||
| Q4 25 | — | 78.9% | ||
| Q3 25 | — | 78.2% | ||
| Q2 25 | — | 79.5% | ||
| Q1 25 | — | 78.7% | ||
| Q4 24 | — | 83.6% | ||
| Q3 24 | — | 83.8% | ||
| Q2 24 | — | 82.8% |
| Q1 26 | — | -1.7% | ||
| Q4 25 | -13.8% | -17.5% | ||
| Q3 25 | -27.0% | -22.2% | ||
| Q2 25 | -24.5% | -24.0% | ||
| Q1 25 | -46.9% | -32.1% | ||
| Q4 24 | -61.1% | -11.1% | ||
| Q3 24 | -59.8% | -16.0% | ||
| Q2 24 | -89.5% | -22.1% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | -16.0% | ||
| Q3 25 | -27.6% | -18.5% | ||
| Q2 25 | -32.0% | -23.5% | ||
| Q1 25 | -48.9% | -26.2% | ||
| Q4 24 | -63.1% | -8.2% | ||
| Q3 24 | -61.7% | -12.4% | ||
| Q2 24 | -91.0% | -18.4% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $-0.23 | ||
| Q3 25 | $-0.94 | $-0.26 | ||
| Q2 25 | $-0.97 | $-0.32 | ||
| Q1 25 | $-1.22 | $-0.32 | ||
| Q4 24 | $-1.54 | $-0.12 | ||
| Q3 24 | $-1.34 | $-0.16 | ||
| Q2 24 | $-1.67 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $179.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $453.5M |
| Total Assets | $689.8M | $1.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $179.3M | ||
| Q4 25 | $322.9M | $883.7M | ||
| Q3 25 | $325.3M | $671.3M | ||
| Q2 25 | $303.0M | $770.9M | ||
| Q1 25 | $300.9M | $567.6M | ||
| Q4 24 | $315.4M | $529.0M | ||
| Q3 24 | $327.3M | $844.8M | ||
| Q2 24 | $315.7M | $582.5M |
| Q1 26 | — | $453.5M | ||
| Q4 25 | $88.3M | $598.7M | ||
| Q3 25 | $73.7M | $604.8M | ||
| Q2 25 | $73.1M | $341.5M | ||
| Q1 25 | $53.2M | $367.7M | ||
| Q4 24 | $57.0M | $455.7M | ||
| Q3 24 | $92.9M | $428.6M | ||
| Q2 24 | $102.9M | $458.6M |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $689.8M | $1.8B | ||
| Q3 25 | $669.3M | $1.7B | ||
| Q2 25 | $639.8M | $1.6B | ||
| Q1 25 | $596.7M | $1.6B | ||
| Q4 24 | $568.5M | $1.7B | ||
| Q3 24 | $561.5M | $1.5B | ||
| Q2 24 | $548.2M | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $55.0M |
| Free Cash FlowOCF − Capex | $-18.7M | $49.0M |
| FCF MarginFCF / Revenue | -9.6% | 28.3% |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $118.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $55.0M | ||
| Q4 25 | $-18.7M | $24.7M | ||
| Q3 25 | $1.0M | $33.4M | ||
| Q2 25 | $-32.4M | $21.3M | ||
| Q1 25 | $-43.4M | $68.0M | ||
| Q4 24 | $-26.2M | $24.3M | ||
| Q3 24 | $-18.6M | $22.5M | ||
| Q2 24 | $-30.1M | $11.7M |
| Q1 26 | — | $49.0M | ||
| Q4 25 | $-18.7M | $20.7M | ||
| Q3 25 | $988.0K | $30.4M | ||
| Q2 25 | $-32.4M | $18.0M | ||
| Q1 25 | $-43.7M | $65.7M | ||
| Q4 24 | $-26.2M | $19.9M | ||
| Q3 24 | $-18.7M | $21.3M | ||
| Q2 24 | $-30.2M | $10.9M |
| Q1 26 | — | 28.3% | ||
| Q4 25 | -9.6% | 12.0% | ||
| Q3 25 | 0.6% | 18.8% | ||
| Q2 25 | -21.6% | 11.8% | ||
| Q1 25 | -36.0% | 48.1% | ||
| Q4 24 | -22.1% | 12.6% | ||
| Q3 24 | -17.9% | 14.4% | ||
| Q2 24 | -34.6% | 8.4% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 2.3% | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 0.0% | 2.2% | ||
| Q1 25 | 0.3% | 1.7% | ||
| Q4 24 | 0.0% | 2.7% | ||
| Q3 24 | 0.1% | 0.8% | ||
| Q2 24 | 0.1% | 0.6% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
VRNS
| SaaS | $161.1M | 93% |
| Term license subscriptions | $6.9M | 4% |
| Maintenance and services | $5.2M | 3% |
